Editor’s Note
**Editor’s Note:** Hugel Aesthetics is strengthening its U.S. foothold by launching a direct sales force for Letybo and rolling out the new K-TOX campaign. The move signals a strategic push to boost brand presence, backed by expanded medical affairs support and ongoing clinical research.
Hugel Aesthetics Expands U.S. Presence with Direct Sales Force for Letybo and New K-TOX Campaign
Hugel Aesthetics is launching a dedicated direct sales and field-based medical affairs organization for letibotulinumtoxinA-wlbg (Letybo) and investing in a new consumer K-TOX campaign, medical congress support, and clinical evidence generation.
“With over 15 years of clinical experience and 44 million treatments performed across more than 70 countries, Letybo is globally trusted – and the recent company investments reflect our long-term vision and dedication for continued expansion in the U.S.,” says Carrie Strom, Hugel President and Global CEO, in a news release. “As one of the newest global aesthetics companies to enter this market, our goal is to be a partner for aesthetic healthcare professionals through scientific education, meaningful customer support and continued innovation that helps clinicians achieve positive patient outcomes and grow their practices.”
The launch of a dedicated U.S. sales force and field-based medical affairs team will provide enhanced customer support and practice resources to help integrate Letybo into clinical practice. The company also invested in its medical congress support and clinical research.
“I’ve been studying neurotoxins for decades, and I value that Hugel invests in crucial channels beyond the product itself to set up practices for success in making informed treatment decisions that meet the ever-evolving needs of our patients,” adds Nashville, TN-based Dermatologist and Dermatologic Surgeon Michael H. Gold, MD, FAAD, also a U.S. Letybo investigator. “Having access to Hugel’s knowledgeable field teams, ongoing clinical education and emerging scientific data helps keep me and my peers ahead of the curve to offer patients innovative solutions that directly impact our business growth.”
Hugel is also introducing K-TOX, an integrated marketing campaign. The campaign highlights the product’s credibility in South Korea, where more than 15 products compete for market share. The campaign also reinforces Hugel’s commitment to delivering clinically proven aesthetic solutions backed by quality, precision and value.
Throughout 2026, Hugel will focus its commercial and medical affairs teams on U.S. strategic accounts, while Benev continues to service other accounts.
